Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2329884 | 1.00 | MME (0.51) | MMESMN1; SMN2MEN1KMT2ASRC | |
| SCHEMBL2522738 | 0.86 | MME (0.44) | MMEMEN1KMT2ASRCACACB | |
| SCHEMBL2520019 | 0.84 | ACACB (0.43) | MMESMN1; SMN2MEN1KMT2AMTNR1A | |
| SCHEMBL4799364 | 0.83 | SRC (0.48) | MMESMN1; SMN2MEN1KMT2ASRC | |
| SCHEMBL762079 | 0.83 | SRC (0.48) | MMESMN1; SMN2MEN1KMT2ASRC | |
| SCHEMBL14278787 | 0.83 | SRC (0.48) | MMESMN1; SMN2MEN1KMT2ASRC | |
| SCHEMBL9462002 | 0.82 | SLC1A2 (0.60) | MMESMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL8602939 | 0.82 | MME (0.49) | MMESMN1; SMN2KMT2ALMNAGAA | |
| SCHEMBL9461816 | 0.82 | SLC1A2 (0.60) | MMESMN1; SMN2KMT2ALMNAHPGD | |
| SCHEMBL9461814 | 0.82 | SLC1A2 (0.60) | MMESMN1; SMN2KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9025275-A | — | — | None | — | — | JP | disclosed |
| EP-2534161-A1 | ENANTIOMERICALLY ENRICHED AMINODIPHOSPHINES AS LIGANDS FOR THE PREPARATION OF CATALYSTS FOR ASYMMETRIC SYNTHESIS | Enantia, S.L. (ES) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309997-A1 | Enantiomerically Enriched Aminodiphosphines as Ligands for the Preparation of Catalysts for Asymmetric Synthesis | ENANTIA, S.L. (ES) | 2012-12-06 | — | — | US | disclosed |
| WO-2011098160-A1 | ENANTIOMERICALLY ENRICHED AMINODIPHOSPHINES AS LIGANDS FOR THE PREPARATION OF CATALYSTS FOR ASYMMETRIC SYNTHESIS | ENANTIA, S.L. (ES) | 2011-08-18 | — | — | WO | disclosed |
| JP-H0925275-A | AMINO ACID ESTER DERIVATIVE AND HERBICIDE CONTAINING THE DERIVATIVE | OTSUKA CHEM CO LTD | 1997-01-28 | — | — | JP | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309997-A1 | Enantiomerically Enriched Aminodiphosphines as Ligands for the Preparation of Catalysts for Asymmetric Synthesis | PHOSPHO1, AASDHPPT, AGPS | MME 1666/4885SMN1; SMN2 4541/4885MEN1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.